Actelion Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Actelion Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH27019D
  • |
  • Pages: 57
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Actelion Pharmaceuticals Ltd (Actelion), subsidiary of Johnson & Johnson is a biopharmaceutical company, which discovers, develops and commercializes innovative treatments for diseases with considerable unmet medical needs. The company focuses on the development of treatments for pulmonary arterial hypertension (PAH). Its PAH franchise products include endothelin receptor antagonists (ERAs) Tracleer (bosentan), Opsumit (macitentan), Veletri (epoprostenol for injection), Ventavis (iloprost) and Uptravi (selexipag). Its specialty products include Valchlor (mechlorethamine), Ledaga (chlormethine) and Zavesca (miglustat). Actelion also offers approved treatments for diseases such as Type 1 Gaucher disease, Niemann-Pick type C disease, digital ulcers in patients with systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma. The company offers its products in various countries across Europe, besides Japan, China, Russia, Mexico and the US. Actelion is headquartered in Allschwil, Switzerland.

Actelion Pharmaceuticals Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Actelion Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deal Details 14

Partnerships 14

Enamine Expands Agreement with Actelion 14

SynAging Extends Agreement with Actelion Pharma 15

Handok Enters into Agreement with Actelion Pharmaceuticals 16

Actelion Forms Joint Venture with Max Planck Society 17

ZoBio Enters Into Drug Discovery Agreement With Actelion Pharma For Fragment Ligands 18

Licensing Agreements 19

Actelion Enters into Licensing Agreement with ReveraGen BioPharma 19

GBC-Atrial Enters into Licensing Agreement with Actelion Pharma 20

Kythera Biopharma Enters into Licensing Agreement with Actelion Pharma 21

Auxilium Pharma Enters Into Licensing Agreement With Actelion Pharma For XIAFLEX 22

Theratechnologies Enters Into Licensing Agreement With Actelion Pharma For Lipodystrophy Drug 24

Equity Offering 25

Actelion Spun Out its Drug Discovery and Early Clinical Pipeline Business 25

Asset Transactions 26

Helsinn Healthcare to Acquire Rights of Valchlor/Ledaga from Actelion Pharma 26

Acquisition 27

Johnson & Johnson Acquires Actelion for USD30 Billion 27

Actelion Plans to Acquire ZS Pharma 29

Actelion Rejects Acquisition Offer from Shire 30

Tetraphase Pharma May Sell Itself 31

Actelion Completes Acquisition Of Ceptaris Therapeutics For USD 250 Million 33

Actelion Pharmaceuticals Ltd-Key Competitors 36

Actelion Pharmaceuticals Ltd-Key Employees 37

Actelion Pharmaceuticals Ltd-Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Recent Developments 42

Financial Announcements 42

Feb 14, 2017: Actelion announces excellent financial results for 2016 42

Corporate Communications 46

Aug 06, 2018: Alzheon appoints former IVAX president, Neil Flanzraich, JD, as vice chairman of board of directors 46

Jun 09, 2017: Publication of Idorsia's prospectus relating to the listing of Idorsia on SIX Swiss Exchange 47

May 15, 2017: Actelion announces changes to its executive team upon completion of the transaction with Johnson & Johnson 49

Product Approvals 50

Aug 30, 2018: Actelion submits application to EMA seeking approval of OPSUMIT (macitentan) for the treatment of Chronic Thromboembolic Pulmonary Hypertension 50

Apr 30, 2018: Actelion Submits Supplemental New Drug Application to US FDA Seeking Approval of OPSUMIT (macitentan) for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH) 52

Clinical Trials 53

Jan 23, 2017: Actelion announces results of the MAESTRO study with macitentan in patients with pulmonary arterial hypertension due to Eisenmenger Syndrome 53

Other Significant Developments 55

May 22, 2017: Actelion provides an update on the progress towards launching Idorsia-Key results for pipeline assets to be developed by Idorsia 55

Appendix 57

Methodology 57

About GlobalData 57

Contact Us 57

Disclaimer 57

List of Figures

Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Actelion Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 11

List of Tables

Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Key Facts 2

Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Actelion Pharmaceuticals Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

Actelion Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Enamine Expands Agreement with Actelion 14

SynAging Extends Agreement with Actelion Pharma 15

Handok Enters into Agreement with Actelion Pharmaceuticals 16

Actelion Forms Joint Venture with Max Planck Society 17

ZoBio Enters Into Drug Discovery Agreement With Actelion Pharma For Fragment Ligands 18

Actelion Enters into Licensing Agreement with ReveraGen BioPharma 19

GBC-Atrial Enters into Licensing Agreement with Actelion Pharma 20

Kythera Biopharma Enters into Licensing Agreement with Actelion Pharma 21

Auxilium Pharma Enters Into Licensing Agreement With Actelion Pharma For XIAFLEX 22

Theratechnologies Enters Into Licensing Agreement With Actelion Pharma For Lipodystrophy Drug 24

Actelion Spun Out its Drug Discovery and Early Clinical Pipeline Business 25

Helsinn Healthcare to Acquire Rights of Valchlor/Ledaga from Actelion Pharma 26

Johnson & Johnson Acquires Actelion for USD30 Billion 27

Actelion Plans to Acquire ZS Pharma 29

Actelion Rejects Acquisition Offer from Shire 30

Tetraphase Pharma May Sell Itself 31

Actelion Completes Acquisition Of Ceptaris Therapeutics For USD 250 Million 33

Actelion Pharmaceuticals Ltd, Key Competitors 36

Actelion Pharmaceuticals Ltd, Key Employees 37

Actelion Pharmaceuticals Ltd, Subsidiaries 38

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

select a license
Single User License
USD 250 INR 17815
Site License
USD 500 INR 35630
Corporate User License
USD 750 INR 53445

NEWSLETTER BY CATEGORY




Testimonials

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com